Sign up Australia
Proactive Investors - Run By Investors For Investors

Pressure BioSciences developing breakthrough processing method for shelf-stable milk, dairy products

The Massachusetts company’s high-pressure Ultra Shear Technology will play a significant role in the preservation of 'clean label' foods and beverages
Pressure BioSciences equipment
Pressure BioSciences provides high-pressure-based technologies, platforms and services to the life sciences market

Pressure BioSciences (OTCMKTS:PBIO) announced Thursday that it is working with researchers at Ohio State University to develop and make available for commercialization a manufacturing technology that will play a role in the in the preservation of "clean label" foods and beverages.

The South Easton, Massachusetts company holds several patents for Ultra Shear Technology, which applies high-pressure levels greater than 20,000 pounds per square inch. The technology would allow companies to offer milk, and healthier drinks and juices by reducing heat exposure in the preservation process through a combined application of elevated pressure, intense shear forces and controlled times and temperatures. 

The collaborative project is funded by a US$891,000 grant from the US Department of Agriculture. Ohio State has granted Pressure BioSciences a US$318,000 sub-contract to build a working benchtop instrument and a pilot plant floor model Ultra Shear Technology machine.

READ: Ohio State scientists to use Pressure BioSciences's Ultra Shear Technology to sterilize 'clean label' food and drinks

Edmund Ting, senior vice president at Pressure BioSciences, will lead the development of the pilot-plant equipment that the researchers at the College of Food, Agricultural, and Environmental Sciences (CFAES) at Ohio State require.

"High Pressure Processing (HPP) has proven to be very effective in reducing food-borne pathogens and extending shelf-life in pre-packaged foods (e.g., juices and ready-to-eat meats), thus eliminating the need for chemical additives. However, HPP remains a batch process not capable of continuous flow, and because it is only a pasteurization process, and does not render food 'commercially sterile,' HPP-processed food must be shipped, stored, and maintained under refrigeration throughout the entire chain of distribution and retail sale,” said Ting, who is a co-inventor of Ultra Shear Technology.

“We believe that Ultra Shear Technology will provide economical solutions to these problems, and will offer an additional, clean label processing choice to both consumers and the food industry," he added.

According to GoCleanLabel.com, "clean label" foods contain "natural, familiar, simple ingredients that are easy to recognize, understand, and pronounce" with no artificial ingredients or synthetic chemicals. The "clean label" food market has been estimated at approximately US$62bn in the US and US$165bn worldwide.

"The ultimate goal of this collaborative project is for consumers to benefit from the increased availability of wholesome, healthy, better-tasting, shelf-stable, clean label liquid food and beverage options,” said Pressure BioSciences CEO Richard T. Schumacher.

“Imagine liquid foods like milk shipped and stored at room temperature for extended periods of time post-processing, while retaining superior nutritional and taste qualities. The advantages and cost-savings to the consumer and dairy industry could be game-changing. The advantages and cost savings to schools, the military, disaster relief agencies, and other such groups could be equally significant,” added the Harvard Medical School-trained serial entrepreneur.

Laying a strong financial foundation

Separately, the CEO said Pressure BioSciences had achieved “nine consecutive quarters” of increased product and services revenue on a year-over-year basis and 2018 was shaping up as a “banner year.”

The company’s total revenue for the opening three months of 2018 rose 11% to US$610,774, up from US$551,357 in the year-ago quarter, thanks to booming sales of the company’s lab instruments which utilize pressure to control bio-molecular interactions.

“We recently initiated the first project utilizing our recently acquired IP from the BaroFold acquisition, and that we believe this new CRO service could generate significant revenue in the near future," said Schumacher.

BIG PICTURE: Zacks upbeat on Pressure BioSciences' growth potential

Pressure BioScience’s Pre-EMT platform – which uses high pressure to help drug companies develop protein-based therapeutics – is being contracted out to an international biopharma company that intends to use it to improve the quality of a key protein drug. The platform is one is the assets Pressure Biosciences acquired as part of its acquisition of all the assets of BaroFold Inc. last December.

"With our core business showing consistent revenue growth, our BaroFold acquisition generating revenue much sooner than planned, and our Ultra Shear Technology platform getting off to an impressive start, we believe Pressure BioSciences has now positioned itself well for rapid, explosive growth in the months and years ahead."

Commencing commercial operations in 2007, Pressure BioSciences is a leader in high-pressure-based technologies, platforms and services to the life sciences market worldwide.

Contact Uttara Choudhury at [email protected]
Follow her on Twitter: @UttaraProactive

View full PBIO profile View Profile

Pressure BioSciences Inc Timeline

Related Articles

myLotus kit
August 06 2018
The expansion drive is targeting an estimated 2.3mln women per year in the areas of Hebei, Shanghai, Beijing, Shangdong, Henan and Liaoning
1527682514_angel-delight.jpg
May 30 2018
The latest fundraiser underscores the fact the life sciences business is well supported in the City
1528305384_Untitled-design-(3).jpg
June 07 2018
Ventripoint received key FDA approval to sell the device with the four-chamber heart analysis last month

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use